Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy

Area of Science:

• Ophthalmology
• Diabetology
• Cell Biology

Background:

• Diabetic retinopathy is a leading cause of vision loss, driven by oxidative stress.
• Current treatments for diabetic retinopathy lack sufficient antioxidant strategies.
• The nuclear factor erythroid-2-related factor 2 (Nrf2) pathway is crucial for cellular antioxidant defense.

Purpose of the Study:

• To investigate the efficacy of a novel Nrf2 activator, dh404, in protecting the retina against diabetes-induced damage.
• To evaluate dh404's impact on the blood-retinal barrier (BRB) and Müller cells in a diabetic rat model.

Main Methods:

• Diabetic and nondiabetic Sprague-Dawley rats were treated with dh404 via gavage for 10 weeks.
• In vitro studies utilized cultured Müller cells exposed to hyperglycemia.
• Assessed vascular leakage, inflammatory mediators, oxidative stress markers, and Nrf2 pathway activation.

Main Results:

• Dh404 prevented retinal and vitreous vascular leakage and reduced levels of VEGF, angiopoietin-2, TNF-α, and IL-6 in diabetic rats.
• Dh404 protected Müller cells from diabetes-induced gliosis and maintained BRB integrity.
• Dh404 increased retinal antioxidant capacity (hemeoxygenase-1, NQO-1, Nrf2) and attenuated oxidative stress markers (dihydroethidium, 8-OHdG).

Conclusions:

• Dh404 demonstrates significant potential in protecting the retina from diabetes-induced damage.
• The Nrf2 activator dh404 may serve as a novel therapeutic strategy to prevent vision loss in diabetic retinopathy.